February 06, 2024
A New York federal judge trimmed a proposed class action against COVID-19 test-maker Co-Diagnostics and its executives, but said investors sufficiently alleged some statements made during the class period misrepresented that sales and demand for the tests were on the decline, and the defendants knew as such.